Table 1.
Patient | Isotype | Level of IgM in patient, mg/dL | Biopsy, % bone marrow infiltration | Prior therapy | Cells inoculated, × 106 | Weeks to detection of IgM | Level of IgM in mouse,*μg/mL | Level of light chain in mouse,*μg/mL |
---|---|---|---|---|---|---|---|---|
1 | IgM κ | 1240 | 90 | RTX, THAL | 5 | 4 | 1.8 | Negative |
2 | IgM κ | 6130 | 60 | Prednisone | 5 | 16 | 10 | Negative |
3 | IgM κ | 4830 | 50 | Fl, RTX | 5 | 6 | 0.6 | NA |
4 | IgM κ | 1430 | 70 | THAL, DEX | 5 | 28 | 2.6 | 0.7 |
5 | IgM λ | 2590 | 60 | RTX | 10 | 4 | 1.5 | Negative |
6 | IgM κ | 2390 | 70-80 | None | 10 | 5 | 2.6 | NA |
7 | IgM, κ | 7630 | 90 | None | 2 | 13 | 0.4 | NA |
8 | IgM,κ | NA | NA | None | 2 | 20 | 0.2 | 0.4 |
9† | IgM κ | 4970 | 95 | CVP, RTX | 2 | 7 | 8.4 | 0.4 |
10† | IgM,κ | 2340 | 50 | None | 2 | 20 | 1.8 | NA |
RTX indicates rituximab; THAL, thalidomide; Fl, fludarabine; NA, not available; DEX, dexamethasone; CVP, cyclophosphamide, vincristine, and prednisone.
At time of first IgM detection.
In these cases, BM cells were CD19-immunomagnetically sorted before mice inoculation into human bone implant.